Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03789721 · ClinicalTrials.gov registry record
Adrenoleukodystrophy National Registry Study
A clinical trial of Adrenoleukodystrophy and ALD (Adrenoleukodystrophy), sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT03789721 is a study of Adrenoleukodystrophy and ALD (Adrenoleukodystrophy) that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 1,000 participants, below the 2,055-participant average among 6 other Adrenoleukodystrophy trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03789721, a study of Adrenoleukodystrophy and ALD (Adrenoleukodystrophy), is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this registry to understand the natural history and disease progression in ALD and potentially develop bio-markers using the biospecimens collected using this registry.
Conditions Studied
Interventions
- OTHER Medical Record Abstraction
- OTHER Biospecimen Sample Collection
Study Locations (1)
Minnesota
- Masonic Cancer Center at University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2030-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03789721
The ClinicalTrials.gov registry entry for NCT03789721 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,055-participant average among 6 other Adrenoleukodystrophy trials with a reported enrollment target (51% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Adrenoleukodystrophy appearing as the primary indexed condition, and to 2 interventions - of which Medical Record Abstraction is the first listed.
NCT03789721 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03789721 about?
NCT03789721 is a clinical study titled "Adrenoleukodystrophy National Registry Study". The aim of this registry to understand the natural history and disease progression in ALD and potentially develop bio-markers using the biospecimens collected using this registry.
What is the current status of trial NCT03789721?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2019-05-01. Estimated completion is 2030-02.
What conditions does trial NCT03789721 study?
This clinical trial studies the following conditions: Adrenoleukodystrophy, ALD (Adrenoleukodystrophy), Cerebral Adrenoleukodystrophy.
What interventions are being tested in trial NCT03789721?
The interventions under investigation include: Medical Record Abstraction (OTHER), Biospecimen Sample Collection (OTHER).
Who is sponsoring clinical trial NCT03789721?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03789721 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adrenoleukodystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Myelin Disorders Biorepository Project
RECRUITING
-
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
RECRUITING · Phase 1
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Human Placental-Derived Stem Cell Transplantation
COMPLETED · Phase 1
-
Stem Cell Transplant for Inborn Errors of Metabolism
COMPLETED · Phase 2
-
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.